Sarah Cannon Research Institute joins Caris’ extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine
IRVING, Texas, October 26, 2023 – Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, has joined the Caris Precision Oncology Alliance™ (POA).
SCRI, a global leader in oncology research, has conducted clinical trials in the community for more than 30 years. Their contributions to pivotal research helped to advance the majority of new cancer therapies approved by the FDA today. Powered by Genospace, SCRI’s personalized medicine program leverages real-world data to advise physicians and biopharma on clinical development and treatment planning for patients based on their unique genetic results.
The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris’ highly sophisticated AI bioinformatics and machine learning capabilities across the company’s massive clinico-genomic database to enable innovative research to improve clinical outcomes for cancer patients.
“SCRI and Caris share a commitment to advancing therapies and expanding access to molecular diagnostic approaches for patients in the community,” said Andrew McKenzie, PhD, Vice President of Personalized Medicine, SCRI; Scientific Director, Genospace. “We are pleased to join the Caris Precision Oncology Alliance, and look forward to the opportunities to leverage comprehensive genomic data to inform clinical development strategies to improve outcomes for people facing cancer.”
“We are thrilled to start working with SCRI investigators and researchers on cutting-edge studies that will help develop innovative therapies and discoveries,” said Chadi Nabhan, MD, MBA, FACP, Chairman of the POA. “Together, we hope to improve the outcomes of patients with cancer.”
The Caris POA includes 89 cancer centers, academic institutions, research consortia and healthcare systems. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker-directed trials sponsored by biopharma. Additionally, POA member institutions have access to the most comprehensive clinico-genomic database in the industry, which includes matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, covering over 1 million data points per patient.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively accruing patients to clinical trials at more than 250 locations in 24 states across the U.S. Learn more about our research offerings.